ClinicalTrials.gg
Status unknownNCT02082054Updated May 30, 2014

StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study

A Phase 2 interventional study of PSE 120 mg, CM 8 mg, Atr 0.36 mg and PSE 120 mg, CM 8 mg, Atr 0.24 mg in Rhinitis, Seasonal, Allergic, sponsored by Magna Pharmaceuticals, Inc.. Status unknown at 4 sites in United States. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-05-30.

Sponsored by Magna Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2014), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
12 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · United States.

Planned enrollment
67th of 101
125 · median 446
Started
2014
with 5 others
Phase 2
20 of 107
none open now
Registered
89th of 107
by date
Lead sponsor
5 of 107
Magna Pharmaceuticals, Inc.

Among the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, this one is the 67th largest by planned enrollment of the 101 interventional ones that give a count, is one of 6 that started in 2014, is one of 20 in phase 2, and was the 89th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

1 of the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 12 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, or all of them as a file.
02

Study summary

This active vs active comparative trial will evaluate the safety and efficacy of incremental doses of atropine in combination with pseudoephedrine 120 mg/chlorpheniramine 8 mg in adult patients with a history of seasonal allergic rhinitis. Hypotheses are defined by total nasal symptom scores (TNSS) recorded by subjects in diaries where efficacy will be established by statistical significance where p \< 0.05.

Read the detailed description

Actives in each of the five study arms:

Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine 0.36 mg Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine 0.24 mg Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine 0.12 mg Pseudoephedrine 120 mg/Chlorpheniramine 8 mg Atropine 0.24 mg

03

Conditions studied

  • Rhinitis, Seasonal, Allergic

Keywords

  • rhinitis
  • seasonal
  • allergic
04

Who can participate

Ages eligible
12 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and females of any ethnic group between 12 and 60 years of age.
  2. History of moderate to severe SAR for at least two years; defined as having a score of 2 or more on a 0-3 point scale
  3. Documentation of sensitivity will be obtained from medical records or positive skin testing or in vitro specific IgE test.
  4. Have a TNSS score of 6 with at least an average of 2.0 in the rhinorrhea sub-score during the placebo-run in phase.
  5. Is a non-pregnant, non-lactating female who is , naturally or surgically sterile, or who agree to use effective methods throughout the course of the study.
  6. If female of , must agree to use listed acceptable birth control methods...
  7. If female of childbearing potential, has a negative urine human chorionic gonadotropin (hCG) pregnancy test at screening
  8. Is able to swallow whole tablets of orally administered medication
  9. Is able to understand and provide signed

Exclusion criteria

Exclusion Criteria:

  1. Has asthma requiring treatment
  2. Is currently undergoing chronic or intermittent use of inhaled, oral, intramuscular, intravenous, and/or potent or super potent topical corticosteroids
  3. Has taken any of the following medications in the indicated time period prior to study enrolment:

    • Intranasal, opthalmic, or systemic corticosteroids (1 month)
    • Intranasal cromolyn (2 weeks)
    • Intranasal or systemic decongestants (3 days)
    • Intranasal or systemic antihistamines (7 days) or leukotriene inhibitors (7 days)
  4. Documented evidence of acute or significant chronic sinusitis, as determined by the individual investigator
  5. Has a history of allergic reaction to or known sensitivity to the active or inactive ingredients in the products used in this study
  6. Chronic use of concomitant medications (e.g., tricyclic antidepressants) that would affect assessment of the effectiveness of the study medication
  7. Rhinitis medicamentosa
  8. A history of glaucoma
  9. Has known or suspected pregnancy, planned pregnancy, or lactation (for female patients)
  10. Is currently receiving immunotherapy, unless at stable maintenance dose for at least 1 month.
  11. Presence of a medical condition that might interfere with treatment evaluation or require a change in therapy.
  12. Plans to travel outside the study area for a substantial portion of the study period
  13. Has a history in the last 2 years or current evidence of abuse of illicit drugs, prescription medications, or alcohol that, in the opinion of the Investigator, would interfere with adherence to study requirements.
  14. Has exposure to any investigational agent within 30 days prior to study entry.
  15. Has mental illness (to be determined by the Investigator)
  16. Has a condition the Investigator believes would interfere with the ability to provide or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
125 participants (estimated)

Study arms

  • Experimental
    PSE 120 mg, CM 8 mg, Atr 0.36 mg

    Pseudoephedrine 120 mg,chlorpheniramine 8 mg, atropine 0.36 mg tablet dosed BID for 7.5 days

    Drug: PSE 120 mg, CM 8 mg, Atr 0.36 mg

  • Experimental
    PSE 120 mg, CM 8 mg, Atr 0.24 mg

    Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg tablets dosed BID for 7.5 days

    Drug: PSE 120 mg, CM 8 mg, Atr 0.24 mg

  • Experimental
    PSE 120 mg, CM 8 mg, Atr 0.12 mg

    Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 dosed BID for 7.5 days

    Drug: PSE 120 mg, CM 8 mg, Atr 0.12 mg

  • Active comparator
    PSE 120 mg, CM 8 mg

    Pseudoephedrine 120 mg, chlorpheniramine 8 mg white, scored, tablets with "M27" on scored side and plain on the other side

    Drug: PSE 120 mg, CM 8 mg

  • Experimental
    Atropine 0.24 mg

    Atropine 0.24 mg tablets dosed BID for 7.5 days

    Drug: Atropine 0.24 mg

Interventions

  • DrugPSE 120 mg, CM 8 mg, Atr 0.36 mg

    Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with "M27" on scored side and plain on the other side

    Also known as: Pseudoephedrine, chlorpheniramine (Chlor-Trimeton), atropine

  • DrugPSE 120 mg, CM 8 mg, Atr 0.24 mg

    Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with "M27" on scored side and plain on the other side

    Also known as: Pseudoephedrine, chlorpheniramine (Chlor-Trimeton), atropine

  • DrugPSE 120 mg, CM 8 mg, Atr 0.12 mg

    Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with "M27" on scored side and plain on the other side

    Also known as: Pseudoephedrine, chlorpheniramine (Chlor-Trimeton), atropine

  • DrugPSE 120 mg, CM 8 mg

    Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID

    Also known as: Pseudoephedrine, chlorpheniramine (Chlor-Trimeton)

  • Atropine sulfate 0.24 mg white, scored, tablets with "M27" on scored side and plain on the other side

    Also known as: atropine sulfate

06

What researchers measure

Primary outcomes

  1. Dose-ranging data for atropin

    To provide dose-ranging data for atropine and select a dose of Atropine for Phase 3 clinical development using Total Nasal Symptom Score (TNSS) as the primary endpoint plus recording of adverse events

    Time frame: 7.5 days

Secondary outcomes

  1. Establish effect size for determining power and TNSS efficacy endpoint

    To establish an effect size of a Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine combination versus Pseudoephedrine 120 mg/Chlorpheniramine 8 mg to statistically power the pivotal phase of the study using TNSS as the primary endpoint

    Time frame: 7.5 days

Other outcomes

  1. Establish safety/efficacy and appropriate dosage interval of investigational formulas

    1. Assess the instantaneous and reflective TNSS scores. 2. To assess the effect of various doses of Atropine in combination with Pseudoephedrine 120 mg/Chlorpheniramine 8 mg on each of the four (4) individual components of the TNSS compared to Pseudoephedrine 120 mg/Chlorpheniramine 8 mg alone 3. To assess if BID dosing is an appropriate dosing interval for the Pseudoephedrine/Chlorpheniramine/Atropine formulation 4. To assess the effect of Atropine 0.24 mg alone on the change from baseline of each of the four (4) individual components of the TNSS 5. To assess the safety and tolerability of Pseudoephedrine 120 mg/Chlorpheniramine 8 mg/Atropine combination products compared to Pseudoephedrine 120 mg/Chlorpheniramine 8 mg product as well as the safety and tolerability of atropine 0.24 mg administered twice/day. 6. To assess the incidence and severity of drowsiness

    Time frame: 7.5 days

07

Study locations

4 sites
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Family Allergy and Asthma Institute
    Louisville, Kentucky 40215, United States
  • National Allergy, Asthma & Urticaria Centers of Charleston, PA
    Charleston, South Carolina 29406, United States
  • Central Texas Health Research
    New Braunfels, Texas 78130, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2014
First posted
Mar 10, 2014
Start
Mar 2014
Primary completionEst.
May 2014
CompletionEst.
May 2014
Last update
May 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02082054
Lead sponsor
Magna Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Mar 10, 2014
Start date
Mar 2014
Primary completion
May 2014 (estimated)
Completion
May 2014 (estimated)
Last update
May 30, 2014

Study contacts

Stephen J Pollard, MD
principal investigator · Family Allergy and Asthma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion